This article was originally published in The Gray Sheet
Inks agreement to sell assets of its drug delivery business to Ortho-McNeil Pharmaceutical, a Johnson & Johnson company. Ortho-McNeil will pay up to $75 mil. in cash, contingent on the achievement of regulatory, technical and commercial milestones for the contraceptive patch Cygnus is developing with R.W. Johnson Pharmaceutical Research Institute, another J&J company. Cygnus will retain those assets relating to a nicotine patch under development. Company Chairman, President and CEO John Hodgman explained that the deal would allow Cygnus to "focus management attention and corporate resources on the GlucoWatch monitor and its propietary sensor technology." The GlucoWatch non-invasive glucose monitoring system premarket approval application will be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Panel on Dec. 9 (1"The Gray Sheet" Nov. 1, In Brief)
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.